Here, we aimed to investigate the synergy between epigenetic reprogramming using DNA demethylation and PD-1/PD-L1 immunotherapy as a potent and novel cancer treatment and whether PD-L1 might be related to a certain CSC profile. This evidence concerns the gene PDCD1 and cancer.